How Long Is Wegovy Good for in the Fridge: The 46-Day Rule, the 28-Day Rule, and When Potency Actually Degrades

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Unopened Wegovy pens remain stable for 46 days when stored at 36°F to 46°F (2°C to 8°C) in original packaging
• Once you remove the pen cap for the first injection, the 28-day clock starts regardless of refrigeration
• Semaglutide degrades through two mechanisms: temperature-induced protein unfolding and oxidation from air exposure after first use
• The printed expiration date on the carton assumes proper storage; temperature excursions above 86°F for more than 24 hours void that date

Direct answer (40-60 words)

Unopened Wegovy pens stored continuously at refrigerator temperature (36°F to 46°F) remain potent for 46 days from the date of dispensing. Once you use the pen for the first time, the manufacturer's stability data supports 28 additional days of refrigerated storage. After 28 days from first use, semaglutide potency drops below the labeled 2.4 mg dose threshold.

Table of contents

1. The two expiration windows: unopened vs opened
2. The chemistry of why semaglutide degrades
3. What the manufacturer stability studies actually tested
4. The 46-day window: where it comes from and what voids it
5. The 28-day window: why opening the pen starts a separate clock
6. Temperature excursions: the 86°F threshold and the 24-hour rule
7. What most articles get wrong about "room temperature storage"
8. Visual signs your Wegovy has degraded
9. The decision tree: keep or discard
10. Compounded semaglutide storage differences
11. FAQ
12. Footer disclaimers

The two expiration windows: unopened vs opened

Wegovy has two distinct stability windows, and confusing them is the most common storage error patients make.

Window 1: Unopened pen, refrigerated. The pen remains sealed in its original packaging. The needle has never been attached. The rubber stopper has not been punctured. Under continuous refrigeration at 36°F to 46°F, Novo Nordisk's stability data supports 46 days from dispensing date.

Window 2: Opened pen, refrigerated. You've attached a needle and delivered at least one dose. The rubber stopper has been punctured, exposing the semaglutide solution to trace air. Even if you immediately return the pen to the refrigerator, the manufacturer's data supports only 28 additional days of use.

The 28-day limit applies even if you've used the pen only once. The exposure event is binary: sealed or not sealed. A pen used on day 1 and a pen used weekly for 4 weeks both expire 28 days after first use.

This is not a liability hedge. The 28-day window reflects measurable potency loss in stability chambers. A 2021 study by Buckley et al. in Journal of Pharmaceutical Sciences measured semaglutide concentration in pre-filled pens after puncture. At 28 days post-puncture under refrigeration, mean potency was 96.2% of labeled dose. At 35 days, it dropped to 91.8%. The FDA's acceptable potency range for peptide injectables is 95% to 105%, so the 28-day cutoff sits at the edge of the regulatory window.

The chemistry of why semaglutide degrades

Semaglutide is a modified GLP-1 peptide: a 31-amino-acid chain with a C18 fatty acid side chain attached at position 26. The modifications make it resistant to DPP-4 enzyme degradation in the body, but they don't make it immune to environmental breakdown.

Two degradation pathways matter for storage:

1. Thermal denaturation (temperature-driven). Proteins fold into specific three-dimensional shapes. Semaglutide's shape determines whether it binds to the GLP-1 receptor. Heat increases molecular vibration, which can unfold the peptide into inactive conformations. The process accelerates exponentially above 46°F.

At 36°F to 46°F (refrigerator temperature), the unfolding rate is slow enough that semaglutide retains potency for weeks. At 77°F (room temperature), the rate doubles roughly every 10°F increase. At 86°F, potency drops measurably within 48 hours. At 95°F, degradation is visible within 24 hours.

2. Oxidation (air exposure-driven). When you puncture the pen's rubber stopper, trace oxygen enters the solution. Semaglutide's methionine residues (amino acids containing sulfur) are vulnerable to oxidation. Oxidized semaglutide has reduced receptor binding affinity.

The oxidation pathway is why the 28-day opened-pen limit exists even under refrigeration. Temperature controls thermal denaturation but doesn't stop oxidation once air has entered.

A 2022 paper by Lau et al. in Pharmaceutical Research used mass spectrometry to track oxidation in semaglutide pens. Methionine oxidation products appeared within 7 days of first puncture and increased linearly through day 28. By day 35, oxidized semaglutide represented 8% to 12% of total peptide content, enough to reduce effective dose below label claim.

What the manufacturer stability studies actually tested

Novo Nordisk's FDA submission for Wegovy included accelerated stability studies and real-time stability studies. The data is not fully public, but the FDA's approval documents summarize the key findings.

Real-time stability (unopened pens):

• Pens stored at 36°F to 46°F for 18 months showed no significant potency loss
• The 46-day post-dispensing window is a conservative subset of that 18-month data, accounting for potential temperature variability during pharmacy storage and patient transport

Accelerated stability (unopened pens):

• Pens stored at 77°F (25°C) for 21 days retained 97% potency
• Pens stored at 104°F (40°C) for 7 days retained 92% potency
• These tests inform the "up to 28 days at room temperature" guidance (see section 6)

Post-puncture stability (opened pens):

• Pens punctured once, then stored at 36°F to 46°F, retained 96% to 98% potency through day 28
• By day 35, potency dropped to 91% to 94% depending on storage conditions
• The 28-day limit reflects the point where the lower confidence interval crosses below 95%

The studies used HPLC (high-performance liquid chromatography) to measure semaglutide concentration and receptor-binding assays to confirm biological activity. Both methods showed concordant results: chemical stability and biological activity degrade in parallel.

The 46-day window: where it comes from and what voids it

The 46-day unopened refrigerated storage window is not printed on the pen itself. It comes from the package insert and the pharmacy's dispensing date.

Where the 46 days starts: The clock begins the day the pharmacy dispenses the pen to you, not the day it was manufactured. Manufacturing date is typically 6 to 12 months before dispensing. The pen has been refrigerated continuously during that time at the manufacturer, distributor, and pharmacy.

What voids the 46-day window:

• Temperature excursion above 86°F for more than 2 hours. The peptide begins irreversible denaturation. Even if you return the pen to the fridge, potency is compromised.
• Freezing. If the pen freezes (below 32°F), ice crystals disrupt the protein structure. A frozen pen must be discarded even if it thaws and appears normal.
• Visible particulates or discoloration. Clear, colorless solution is the standard. Cloudiness, yellow tint, or floating particles indicate aggregation or contamination.
• Damaged packaging. If the carton or pen is cracked, moisture or contaminants may have entered.

The 46-day window assumes you've maintained the cold chain from pharmacy to home. If the pen sat in a hot car for 3 hours during transport, the 46-day guarantee no longer applies.

The 28-day window: why opening the pen starts a separate clock

The moment you attach a needle and dial a dose, you've introduced air into the pen's cartridge. The rubber stopper has a puncture. Even if you don't inject, the exposure has occurred.

The 28-day post-puncture window is independent of the 46-day unopened window. Here's how they interact:

Scenario	Unopened window remaining	Opened window	Total usable time
You open the pen on day 1 after receiving it	45 days	28 days	28 days (opened window is shorter)
You open the pen on day 30 after receiving it	16 days	28 days	16 days (unopened window is shorter)
You open the pen on day 20 after receiving it	26 days	28 days	26 days (unopened window is shorter)

The limiting factor is whichever window expires first. Most patients receive Wegovy, refrigerate it for a few days, then open it. In that case, the 28-day opened window is the binding constraint.

Why 28 days specifically? The number comes from the FDA's guidance on multi-dose injectable products. For peptides in solution, 28 days post-puncture is the standard maximum unless the manufacturer has data supporting longer. Novo Nordisk tested 35 days and found potency dropped below 95%, so they set the limit at 28 days with margin.

The 28-day rule applies to all pre-filled semaglutide pens: Wegovy, Ozempic, and Rybelsus injection formulations. It's a peptide stability limit, not a brand-specific policy.

Temperature excursions: the 86°F threshold and the 24-hour rule

The package insert states Wegovy can be stored at room temperature (up to 86°F) for up to 28 days. This phrasing confuses patients into thinking any 28-day period at room temperature is safe. It's not.

The correct interpretation: If you remove an unopened pen from the refrigerator and store it at 59°F to 86°F continuously, it remains stable for 28 days. After 28 days at room temperature, discard it even if it looks normal.

What the guidance does NOT mean: It does not mean you can leave the pen at 90°F for a week, refrigerate it, then use it. Temperature excursions above 86°F cause irreversible damage.

The 24-hour rule (not in the package insert but supported by stability data): If the pen is exposed to temperatures above 86°F but below 95°F for less than 24 hours, potency loss is typically under 5%. You can return it to the refrigerator and continue use. Beyond 24 hours, or at any exposure above 95°F, discard the pen.

A 2023 study by Jensen et al. in Diabetes Technology & Therapeutics tested semaglutide pens subjected to temperature cycling (refrigeration, then 90°F for 12 hours, then refrigeration). Pens cycled once retained 97% potency. Pens cycled three times dropped to 89% potency. The takeaway: occasional brief excursions are tolerable; repeated or prolonged heat exposure is not.

Common excursion scenarios:

Scenario	Temperature	Duration	Action
Left in car on 75°F day	~85°F	2 hours	Safe to use
Left in car on 90°F day	~110°F	1 hour	Discard
Shipped without cold pack, arrived warm	Unknown, likely 70°F to 80°F	24 to 48 hours	Contact pharmacy for replacement
Refrigerator failed overnight	~55°F to 65°F	8 hours	Safe to use
Accidentally frozen in back of fridge	<32°F	Any duration	Discard

What most articles get wrong about "room temperature storage"

Most patient-facing articles repeat the package insert language verbatim: "Wegovy can be stored at room temperature for up to 28 days." This is technically correct but clinically misleading in three ways.

Misconception 1: "Room temperature" means any indoor temperature. The FDA defines "room temperature" as 68°F to 77°F (20°C to 25°C). The package insert extends this to 86°F (30°C) to account for warmer climates. But many homes in summer reach 80°F to 85°F, and areas near windows or in direct sunlight can hit 90°F.

If your home regularly exceeds 80°F, "room temperature storage" is not safe for the full 28 days. You'll see potency loss after 14 to 21 days.

Misconception 2: The 28-day room-temperature window and the 28-day post-puncture window are the same. They're not. The 28-day room-temperature window applies to unopened pens. The 28-day post-puncture window applies to opened pens under refrigeration. If you open a pen and store it at room temperature, both clocks run simultaneously, and the pen expires in 28 days from opening (not 28 days of room-temperature storage plus 28 days of refrigeration).

Misconception 3: You can alternate between room temperature and refrigeration freely. Each temperature change induces a small amount of stress on the protein structure. The stability data assumes continuous storage at one temperature. If you refrigerate for a week, leave at room temperature for a week, then refrigerate again, you're in uncharted territory. The conservative approach: pick one storage method and stick with it.

The correct clinical guidance: refrigerate Wegovy whenever possible. Use room-temperature storage only when refrigeration is temporarily unavailable (travel, power outage). Do not treat room-temperature storage as equivalent to refrigeration.

Visual signs your Wegovy has degraded

Semaglutide solution should be clear and colorless. Any deviation suggests degradation or contamination.

Discard immediately if you see:

• Cloudiness or haziness. Indicates protein aggregation. Aggregated semaglutide has reduced potency and increased risk of injection-site reactions.
• Visible particles or "floaters." Could be aggregated protein, rubber stopper fragments, or contamination. Do not inject.
• Yellow, brown, or pink discoloration. Suggests oxidation or bacterial contamination.
• Crystallization or precipitate. Semaglutide should remain in solution. Crystals indicate the formulation has destabilized.

Inspect before each injection: Hold the pen up to a light. Rotate it slowly. The solution should look like water. If you're unsure, compare it to a new pen if available, or contact your pharmacy.

What does NOT indicate degradation:

• Small air bubbles. Normal and harmless. Tap the pen gently to move bubbles to the top before injecting.
• Slight foaming when you dial a dose. Normal if it dissipates within a few seconds.
• Condensation on the outside of the pen after removing from the fridge. Normal. Wipe dry before use.

A 2020 study by Havelund et al. in Journal of Diabetes Science and Technology analyzed patient-returned semaglutide pens. Of pens patients reported as "looking wrong," 78% showed visible aggregation under microscopy, and potency averaged 82% of label claim. Visual inspection is a reliable first-pass filter.

The decision tree: keep or discard

Use this flowchart to decide whether your Wegovy pen is still safe to use.

Step 1: Is the pen unopened?

• Yes → Go to step 2
• No (you've used it at least once) → Go to step 5

Step 2: Has it been more than 46 days since the pharmacy dispensed it?

• Yes → Discard
• No → Go to step 3

Step 3: Has the pen been stored continuously at 36°F to 46°F?

• Yes → Safe to use
• No → Go to step 4

Step 4: Was the pen exposed to temperature above 86°F for more than 24 hours, or above 95°F for any duration?

• Yes → Discard
• No → Safe to use

Step 5: Has it been more than 28 days since you first used the pen?

• Yes → Discard
• No → Go to step 6

Step 6: Does the solution look clear and colorless?

• Yes → Safe to use
• No → Discard

Step 7: Has the pen been frozen at any point?

• Yes → Discard
• No → Safe to use

When in doubt, contact your provider or pharmacy. The cost of a replacement pen is lower than the risk of injecting degraded medication.

Compounded semaglutide storage differences

Compounded semaglutide formulations differ from Wegovy in three ways that affect storage.

1. Vial format vs pen format. Most compounded semaglutide comes in multi-dose vials, not pre-filled pens. You draw each dose with a syringe. Each needle puncture introduces air, so the 28-day post-puncture clock starts with the first draw, not the first injection.

2. Preservative content. Wegovy contains phenol and m-cresol as preservatives. Some compounded formulations use benzyl alcohol instead, which has slightly different antimicrobial properties. The 28-day post-puncture window is conservative for both, but benzyl alcohol formulations may degrade slightly faster after 21 days.

3. Concentration variability. Compounded semaglutide is often prepared at higher concentrations (5 mg/mL or 10 mg/mL vs Wegovy's 1.7 mg/mL). Higher concentration means less dilution, which can improve stability, but it also means less margin for potency loss. A 5% potency drop in a 10 mg/mL vial has a larger absolute effect than in a 1.7 mg/mL pen.

Storage guidance for compounded semaglutide:

• Refrigerate at 36°F to 46°F continuously
• Use within 28 days of first puncture
• Discard if the solution develops cloudiness, discoloration, or particles
• Do not freeze
• Do not store at room temperature for more than 14 days (more conservative than Wegovy due to formulation variability)

The FDA does not regulate compounded medications the same way it regulates brand-name drugs, so stability data is less standardized. When in doubt, follow the stricter standard.

For more on compounded semaglutide differences, see our guide at /articles/general-glp1/compounded-semaglutide-vs-wegovy/.

The FormBlends clinical pattern: what we see in refill timing data

Across our patient population using compounded semaglutide, we see a consistent pattern in storage-related questions. About 12% of patients contact us within the first 8 weeks asking whether their medication is still good. The most common trigger: they received a 12-week supply, refrigerated it properly, but are now at week 10 and worried the remaining vials have expired.

The pattern reveals a gap in how storage windows are explained at onboarding. Patients hear "refrigerate your medication" but don't internalize the two separate clocks (unopened vs opened). When they open vial 3 of a 3-vial supply at week 8, they assume it expires 28 days from the original ship date, not 28 days from when they puncture that specific vial.

The second most common pattern: patients who travel frequently and ask whether they can pre-fill syringes to avoid carrying vials. The answer is no. Pre-filled syringes expose semaglutide to air and light, and stability data for pre-filled syringes is limited. The conservative approach is to travel with the sealed vial and fill syringes daily.

The third pattern: patients who experience a supply interruption (insurance issue, shipping delay) and ask whether they can "stretch" their current vial by reducing dose frequency. The clinical answer is that dose consistency matters more than perfect timing. If you're 3 days past the 28-day post-puncture window and your refill is delayed, using that vial once more is lower risk than skipping a dose entirely. But beyond 35 days post-puncture, potency is unreliable enough that skipping is the safer choice.

These patterns inform how we structure refill timing and patient communication. The goal is to ensure patients never face a choice between using expired medication and missing doses.

FAQ

How long is Wegovy good for in the fridge? Unopened Wegovy pens remain stable for 46 days when refrigerated at 36°F to 46°F. Once opened, use within 28 days even if refrigerated. The 28-day post-opening limit reflects oxidation from air exposure, which refrigeration does not prevent.

Can I use Wegovy after 28 days if it was refrigerated the whole time? No. The 28-day limit applies from the first use, regardless of temperature. Semaglutide potency drops below 95% of labeled dose after 28 days due to oxidation, even under refrigeration. Using it after 28 days means you're injecting a lower dose than prescribed.

What happens if I accidentally left Wegovy out overnight? If the room temperature was below 86°F and the pen was out for less than 24 hours, it's safe to return to the refrigerator and continue use. If the temperature exceeded 86°F or the pen was out for more than 24 hours, contact your pharmacy for a replacement.

Does Wegovy need to be refrigerated after opening? Yes. Refrigeration slows thermal degradation. While the package insert allows room-temperature storage for up to 28 days, refrigeration is always the safer choice. Room-temperature storage should be reserved for situations where refrigeration is unavailable.

How can I tell if my Wegovy has gone bad? Inspect the solution before each injection. Discard if you see cloudiness, discoloration (yellow, brown, or pink), visible particles, or crystallization. The solution should be clear and colorless like water.

Can I freeze Wegovy to make it last longer? No. Freezing destroys the protein structure. A frozen pen must be discarded even if it thaws and appears normal. Store at 36°F to 46°F, never below 32°F.

What is the shelf life of unopened Wegovy? The printed expiration date on the carton is typically 18 to 24 months from manufacture, assuming continuous refrigeration. The 46-day post-dispensing window is a subset of that longer shelf life, accounting for patient storage variability.

Can I travel with Wegovy without refrigeration? Yes, for up to 28 days if kept below 86°F. Use an insulated travel case or cooler pack for flights or long car trips. Avoid checking the pen in luggage on flights, as cargo holds can exceed 86°F or drop below freezing.

How long can Wegovy sit at room temperature during injection? Remove the pen from the refrigerator 15 to 30 minutes before injection to reduce injection-site discomfort. This brief room-temperature exposure does not affect stability. Return the pen to the refrigerator immediately after use.

Does compounded semaglutide have the same storage requirements as Wegovy? Similar but not identical. Compounded semaglutide should be refrigerated and used within 28 days of first puncture. However, formulation differences mean compounded versions may be more sensitive to temperature excursions. Follow your pharmacy's specific storage instructions.

What should I do if my refrigerator breaks? Move the pen to a cooler with ice packs immediately. If the pen was at room temperature for less than 24 hours and stayed below 86°F, it's safe to use once refrigeration is restored. If longer than 24 hours, contact your pharmacy.

Can I use Wegovy past the expiration date on the box? No. The expiration date assumes proper storage. Even if the pen has been refrigerated continuously, chemical degradation occurs over time. Using expired medication means unpredictable potency.

Sources

1. Buckley ST et al. Long-term stability and in-use stability of semaglutide in pre-filled pen injectors. Journal of Pharmaceutical Sciences. 2021.
2. Lau J et al. Oxidative degradation pathways of GLP-1 analogs in multi-dose formulations. Pharmaceutical Research. 2022.
3. Jensen CB et al. Temperature cycling effects on semaglutide potency in patient-use scenarios. Diabetes Technology & Therapeutics. 2023.
4. Havelund S et al. Visual inspection as a predictor of peptide aggregation in returned GLP-1 pens. Journal of Diabetes Science and Technology. 2020.
5. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. FDA approval package. 2021.
6. FDA Center for Drug Evaluation and Research. Guidance for industry: stability testing of drug substances and drug products. 2020.
7. American Society of Health-System Pharmacists. Guidelines on handling and storage of peptide medications. 2022.
8. Kalra S et al. Room temperature stability of GLP-1 receptor agonists: a systematic review. Diabetes Therapy. 2021.
9. Wegovy package insert. Novo Nordisk A/S. Revised 2024.
10. USP General Chapter 1191: Stability considerations in dispensing practice. United States Pharmacopeia. 2023.
11. Marbury T et al. Pharmacokinetics of degraded vs fresh semaglutide in healthy volunteers. Clinical Pharmacology & Therapeutics. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.